Vir Biotechnology, Inc. (VIR) Stock
6 of the hedge funds AlphaScala tracks reported VIR in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Point72's at $57.74M. Company insiders reported 0 open-market buys and 2 sales on SEC Form 4 in the 90 days to Nov 10, 2026.
Which hedge funds own VIR?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Point72 Steve Cohen | 5.67M | $57.74M | +190% |
| Renaissance Technologies Jim Simons (founder) | 1.02M | $10.36M | +34% |
| Citadel Ken Griffin | 991K | $10.10M | -53% |
| D.E. Shaw David Shaw | 416K | $4.24M | -49% |
| Hussman Investment Trust John Hussman | 105K | $1.17M | NEW |
| Millennium Management Israel Englander | 48K | $489.0K | -90% |
13F holdings as of Sep 30, 2026
Explore all tracked funds →Are Vir Biotechnology, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 3, 26 | De Verneuil Vanina | EVP, General Counsel, Corp Sec | SELL | 2.4K | $27K |
| Nov 2, 26 | De Verneuil Vanina | EVP, General Counsel, Corp Sec | SELL | 1.3K | $15K |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →VIR price chart
Powered by TradingViewWhat does Vir Biotechnology, Inc. do?
Vir Biotechnology Inc. is a clinical-stage biopharmaceutical company that discovers, develops, and advances immune-based therapies to treat and prevent serious infectious diseases and cancer. The company leverages its next-generation antibody platform and PRO-XTEN protease-releasable masking technology to power the immune system against unmet medical needs. Its lead program features the combination of tobevibart, a broadly neutralizing monoclonal antibody, and elebsiran, a siRNA targeting hepatitis B virus, in Phase 3 trials through the ECLIPSE registrational program for chronic hepatitis delta virus. In oncology, Vir Biotechnology advances PRO-XTEN dual-masked T-cell engagers, including VIR-5500 targeting PSMA for metastatic castration-resistant prostate cancer, VIR-5818 for HER2-expressing tumors, and VIR-5525 for EGFR-expressing solid tumors, all in Phase 1 development. Preclinical efforts target influenza, RSV, human metapneumovirus, HPV, HIV, and other indications. Founded in 2016 and headquartered in San Francisco, California, Vir Biotechnology focuses on immunology-driven innovation across infectious diseases and oncology to deliver potentially transformative medicines.